16012-70-7

Basic information

• Product Name: Z-ALA-ALA-OH
• Synonyms: N-CARBOBENZOXY-L-ALANYL-L-ALANINE;Z-ALA-ALA-OH;Z-L-ALANYL-L-ALANINE;N-cbz-ala-ala;L-alanyl(benzyloxycarbonyl)-L-alanine;N-ALPHA-CBZ-ALANYL-ALANINE;Cbz-Ala-Ala-OH;Cbz-L-Ala-L-Ala-OH
• CAS NO: 16012-70-7
• Molecular Formula: C₁₄H₁₈N₂O₅
• Molecular Weight: 294.3
• EINECS: 240-149-0
• Mol File: 16012-70-7.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 573°Cat760mmHg
• Flash Point: 300.4°C
• Appearance: /
• Density: 1.252g/cm³
• Vapor Pressure: 5.7E-14mmHg at 25°C
• Refractive Index: 1.543
• Storage Temp.: -15°C
• CAS DataBase Reference: Z-ALA-ALA-OH(CAS DataBase Reference)
• NIST Chemistry Reference: Z-ALA-ALA-OH(16012-70-7)
• EPA Substance Registry System: Z-ALA-ALA-OH(16012-70-7)

Safety Data

• Hazardous Substances Data: 16012-70-7(Hazardous Substances Data)

Usage

Chemical Properties

White to off-white powder

InChI:InChI=1/C14H18N2O5/c1-9(12(17)15-10(2)13(18)19)16-14(20)21-8-11-6-4-3-5-7-11/h3-7,9-10H,8H2,1-2H3,(H,15,17)(H,16,20)(H,18,19)

Upstream product

• 56-41-7 L-alanin 
• 3401-36-3 (N-benzyloxycarbonyl)-L-alanine N-hydroxysuccinimide ester 
• 2483-51-4 N-[(benzyloxy)carbonyl]-L-alanyl-L-alanine methyl ester 
• 3182-95-4 L-Phenylalaninol 
• 50465-92-4 N-benzyloxycarbonyl-alanyl-alanyl-arginine 
• 54865-22-4 N-benzyloxycarbonyl-alanyl-alanyl-leucine 
• 1142-20-7 N-Cbz-Ala 
• 3282-30-2 pivaloyl chloride 
• 49760-60-3 N-benzyloxycarbonyl-L-alanyl chloride 
• 91-00-9 Benzhydrylamine 
• 119706-33-1 TFA salt of alanine N-benzhydryl-glycolamide ester 
• 119706-04-6 BOC-Ala-OBg 
• 10254-07-6 N-benzhydryl-2-chloroacetamide 
• 4132-86-9 N-benzyloxycarbonylalanine 

Downstream Products

• 1948-31-8 di-L-alanine 
• 90606-05-6 6-(N-carbobenzoxy-L-alanyl-L-alanylamido)quinoline 
• 16946-96-6 N-Cbz-L-alanyl-L-alanine succinimido ester 
• 113719-28-1 ester ethylique de l'acide (N-benzyloxycarbonyl)-L-alanyl-L-(amino-1)-ethylphosphonique 
• 123709-02-4 benzyloxycarbonyl-L-alanyl-L-alanyl-L-proline 2-phenylethylamide 
• 50300-49-7 Z-Ala-Ala-Phe-OH 
• 35766-23-5 Cbz-Ala-Ala-Gly-O-t-Bu 
• 129221-00-7 benzyl ((S)-1-(((S)-1-hydroxypropan-2-yl)amino)-1-oxopropan-2-yl)carbamate 
• 139161-70-9 2-(3-(N-(N-Benzyloxycarbonyl)-(S)-alanyl-(S)-alanyl)aminopyrrolidin-1-yl)-9-(2,4-difluorophenyl)-3-fluoro-6H-6-oxopyrido[1,2-a]pyrimidine-7-carboxylic acid benzyl ester 
• 139161-86-7 2-{(2S,4S)-4-[(S)-2-((S)-2-Benzyloxycarbonylamino-propionylamino)-propionylamino]-2-methyl-pyrrolidin-1-yl}-9-(2,4-difluoro-phenyl)-3-fluoro-6-oxo-6H-pyrido[1,2-a]pyrimidine-7-carboxylic acid benzyl ester 
• 1142-20-7 N-Cbz-Ala 
• 5673-69-8 N-benzyloxycarbonyl-L-alanyl-L-alanine ethyl ester 
• 60625-90-3 Cbz-alanine ethyl ester 
• 5748-17-4 Benzyloxycarbonyl-L-alanyl-L-alanine-p-nitrophenyl ester 

Relevant articles and documents

Optimization and anti-cancer properties of fluoromethylketones as covalent inhibitors for ubiquitin C-terminal hydrolase L1

The deubiquitinating enzyme (DUB) UCHL1 is implicated in various disease states including neurodegenerative disease and cancer. However, there is a lack of quality probe molecules to gain a better understanding on UCHL1 biology. To this end a study was carried out to fully characterize and optimize the irreversible covalent UCHL1 inhibitor VAEFMK. Structure-activity relationship studies identified modifications to improve activity versus the target and a full cellular characterization was carried out for the first time with this scaffold. The studies produced a new inhibitor, 34, with an IC50 value of 7.7 μM against UCHL1 and no observable activity versus the closest related DUB UCHL3. The molecule was also capable of selectively inhibiting UCHL1 in cells and did not demonstrate any discernible off-target toxicity. Finally, the molecule was used for initial probe studies to assess the role of UCHL1 role in proliferation of myeloma cells and migration behavior in small cell lung cancer cells making 34 a new tool to be used in the biological evaluation of UCHL1.

Legumain Activated Doxorubicin Derivative as well as Preparation Method and Application Thereof

The present invention discloses doxorubicin derivatives for targeted activation by Legumain, its preparation method and use. The doxorubicin derivatives are obtained by condensation between the amino group of compound A and the carboxyl group of compound B and have the following structure: compounds A and B have the following structures, respectively: wherein R3 in compound B is Leu or absent; R4 is any one amino acid selected from the group consisting of Ala and Thr; R5 is any one amino acid selected from the group consisting of Ala, Thr and Asn; R6 is wherein n=1-20; or wherein R7 is substituted or unsubstituted, linear or branched, saturated or unsaturated C1-C20 fatty hydrocarbon, or substituted or unsubstituted C6-C20 aromatic hydrocarbon. The doxorubicin derivatives of the present invention are specifically tumor-targeted and have a long in vivo metabolic half-life, as compared with doxorubicin. They exhibit an efficient and safe anti-tumor effect and could be used to prepare an anti-tumor drug.

Carboxypeptidase from Streptomyces bikiniensis: Primary structure, isolation, and properties

A metallocarboxypeptidase produced by Streptomyces bikiniensis 27 strain (VKPM Ac-1783) (CPSb) was purified and characterized. The enzyme cleaves both basic and hydrophobic C-terminal amino acid residues from synthetic peptides, that is, it possesses specificity of mammalian carboxypeptidases A and B. The enzyme also hydrolyzes peptides bearing glutamic acid at the C-end. CPSb exhibits its maximal activity at pH 7.0-7.6 and 55°C. The nucleotide sequence encoding the mature CPSb in S. bikiniensis 27 (VKPM Ac-1783) genome (Accession No. GU362077) was determined. It is shown that the primary structure of the mature enzyme has a moderate degree of identity with orthologs from Streptomyces griseus (79% identity) and Streptomyces avermitilis (85% identity).